John Bernard Payne insider trades: Zivo Bioscience (ZIVO) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where John reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 26, 2026 | ZIVO | ↑ Buy | 11,709 | $8.54 | $100K | Direct | Jan 28, 2026 (2d) |
| Oct 16, 2024 | ZIVO | ↑ Buy | 6,343 | $15.76 | $100K | Direct | Oct 16, 2024 (0d) |
| Dec 19, 2022 | ZIVO | ↑ Buy | 57 | $2.50 | $143 | Direct | Dec 20, 2022 (1d) |
| Jan 27, 2022 | ZIVO | ↑ Buy | 9,168 | $2.50 | $23K | Direct | Jan 28, 2022 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ZIVO insiders
Open-market trades in the last 12 months
About John Bernard Payne's insider trades
John Bernard Payne is President and CEO at Zivo Bioscience (ZIVO). Since Jan 27, 2022, John has reported 4 open-market purchases worth $223K and no sales on SEC Form 4. In the last 12 months: 1 buy ($100K).
Their filings also include grants and awards (6 filings), option exercises (6 filings), other transactions (2 filings), shares returned to the company (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ZIVO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.